EXTRAWELL PHAR(00858) issues a profit warning, expecting to incur a loss of at least HK$950 million for the year, a turnaround from profit to loss compared to the previous year.
Jingyou Pharmaceutical (00858) announces that the Group expects to record a loss of at least HK$950 million for the year ending March 31, 2026, compared to a profit recorded for the year ending March 31, 2025.
EXTRAWELL PHAR(00858) announced that the group is expected to record a loss of at least HK$950 million for the year ending March 31, 2026, compared to a profit for the year ending March 31, 2025. The expected reversal from profit to loss is mainly due to several non-cash items, including (i) unrealized losses of approximately HK$800 million to HK$850 million on investments in convertible bonds issued by STARCOIN GROUP Limited (whose shares were suspended from trading on the Stock Exchange on May 6, 2026), while the same project recorded fair value gains in the corresponding period last year; and (ii) impairment provisions totaling approximately HK$140 million on the equity investment in a joint venture company and on loans receivable from that joint venture company. The performance of the group's operating segments remains stable for the year ending March 31, 2026.
Related Articles

KML TECH (08065) releases annual performance, with a net loss of 11.4 million Hong Kong dollars.

RUIFENG RENEW (00527) plans to offer a discount of approximately 15.4% for the placement of up to 343 million shares, raising approximately HK$1.857 billion net.

US Stock Market Move | Cloud computing concept stock opens low and rises high, NEBIUS (NBIS.US) up more than 2%.
KML TECH (08065) releases annual performance, with a net loss of 11.4 million Hong Kong dollars.

RUIFENG RENEW (00527) plans to offer a discount of approximately 15.4% for the placement of up to 343 million shares, raising approximately HK$1.857 billion net.

US Stock Market Move | Cloud computing concept stock opens low and rises high, NEBIUS (NBIS.US) up more than 2%.

RECOMMEND





